Century Therapeutics, Inc.
Biotechnology company developing allogeneic, iPSC-derived immune cell therapies for cancer and autoimmune diseases. Integrates multiplex genome editing, CAR and binder engineering, tunable feeder-free iPSC differentiation to NK and αβ T cells, scaled suspension bioreactor manufacturing, and translational preclinical and early-phase clinical development.
Industries
Nr. of Employees
medium (51-250)
Century Therapeutics, Inc.
Patents
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-12269888-B2
View DetailsArtificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-11661459-B2
View Details
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-12269888-B2
View DetailsArtificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-11661459-B2
View DetailsProducts
CNTY-101
Allogeneic, iPSC-derived CD19-targeted natural killer cell product engineered with multiple precision edits for immune evasion, a surface elimination tag enabling antibody-mediated depletion, and a secreted IL-15 transgene to enhance persistence; evaluated in preclinical potency assays and in a Phase I dose-escalation clinical study.
CNTY-813
iPSC-derived islet cell replacement product engineered to reduce immune recognition (HLA edits and immune-evasion strategies) intended for islet transplantation to treat type 1 diabetes.
CNTY-308
iPSC-derived αβ CAR-T cell product engineered for CD19 targeting and immune evasion; designed to provide an allogeneic, off-the-shelf T cell therapy option for B-cell-mediated diseases.
CNTY-101
Allogeneic, iPSC-derived CD19-targeted natural killer cell product engineered with multiple precision edits for immune evasion, a surface elimination tag enabling antibody-mediated depletion, and a secreted IL-15 transgene to enhance persistence; evaluated in preclinical potency assays and in a Phase I dose-escalation clinical study.
CNTY-813
iPSC-derived islet cell replacement product engineered to reduce immune recognition (HLA edits and immune-evasion strategies) intended for islet transplantation to treat type 1 diabetes.
CNTY-308
iPSC-derived αβ CAR-T cell product engineered for CD19 targeting and immune evasion; designed to provide an allogeneic, off-the-shelf T cell therapy option for B-cell-mediated diseases.
Expertise Areas
- Allogeneic iPSC-derived immune cell development
- Multiplex genome editing and targeted transgene insertion
- CAR and binder engineering for cellular therapeutics
- NK-inhibitory receptor agonist design and binder discovery
Key Technologies
- Induced pluripotent stem cell (iPSC) reprogramming and clonal master cell banking
- CRISPR-mediated homology-directed repair (HDR) and multiplex editing
- Chimeric antigen receptor (CAR) engineering
- Trans antigen signaling receptors (TASR) and VHH/scFv binder engineering
News & Updates
Ongoing Phase I, multicenter, open-label dose-escalation study reporting safety, PK (ddPCR/cell-free DNA), and preliminary efficacy (CRR/ORR) data for an allogeneic iPSC-derived NK product in relapsed/refractory CD19-positive B-cell malignancies.
Poster presenting in vitro and ex vivo potency data versus primary CAR-T, cytokine secretion profiles, ADCC susceptibility, persistence enhancement with IL-15 and exogenous IL-2, and immune-evasion mechanisms.
Presentation describing feeder-free scalable differentiation to CD4+ and CD8+ αβ iPSC-CAR-T cells that expand on antigen engagement, secrete IL-2, and control tumor models with detectable in vivo persistence.
Study presenting TASR-mediated CD300a agonism and VHH binder engineering that enhances survival of HLA-deficient allogeneic T cells against NK cell and PBMC challenges and improves CAR-T function under allogeneic pressure.
Poster describing transition to suspension bioreactors, process optimizations, and yield and cost improvements for allogeneic iPSC-derived cell therapies.
Ongoing Phase I, multicenter, open-label dose-escalation study reporting safety, PK (ddPCR/cell-free DNA), and preliminary efficacy (CRR/ORR) data for an allogeneic iPSC-derived NK product in relapsed/refractory CD19-positive B-cell malignancies.
Poster presenting in vitro and ex vivo potency data versus primary CAR-T, cytokine secretion profiles, ADCC susceptibility, persistence enhancement with IL-15 and exogenous IL-2, and immune-evasion mechanisms.
Presentation describing feeder-free scalable differentiation to CD4+ and CD8+ αβ iPSC-CAR-T cells that expand on antigen engagement, secrete IL-2, and control tumor models with detectable in vivo persistence.
Study presenting TASR-mediated CD300a agonism and VHH binder engineering that enhances survival of HLA-deficient allogeneic T cells against NK cell and PBMC challenges and improves CAR-T function under allogeneic pressure.
Poster describing transition to suspension bioreactors, process optimizations, and yield and cost improvements for allogeneic iPSC-derived cell therapies.